Prognostic Value of Galectin Expression in Patients with Breast Cancer: Systematic Review and Meta-Analysis

Ramos-Martínez, Juan Carlos; Altamirano-Gómez, Gerardo; Ramos-Marinez, Ivan; Valencia, Jorge; Hernández-Zimbrón, Luis Fernando; Hernández‐Juárez, Jesús; Patricia, Echeverría-Vásquez,; Hernández-González, Leticia; Campos, Eduardo Pérez; Mayoral, Eduardo Pérez-Campos; Ramos-Martínez, E

doi:10.1016/j.clbc.2021.12.011

Cited by 2 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future studies need to evaluate other types of galectins and determine their cellular localization. It has already been suggested that the potential prognostic value of galectins depends on cellular localization [ 6 , 60 , 61 ].…”

Section: Discussionmentioning

confidence: 99%

“…Among the proteins that have been investigated in neurodegenerative diseases, we have galectins, which are a group of lectins with an affinity for structures with β-galactoside [ 3 ]. Galectins can be localized in different compartments such as the nucleus, cytoplasm, and extracellular space, and their functions depend on the compartment where they are localized [ 4 , 5 , 6 ]. Seventeen types of galectins have been described, of which the most studied are galectin-1 and galectin-3.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between Galectin Levels and Neurodegenerative Diseases: Systematic Review and Meta-Analysis

Ramos-Martínez

Ramos-Martínez²,

Sánchez‐Betancourt³

et al. 2022

Biomolecules

Self Cite

View full text Add to dashboard Cite

Galectins are a family of proteins with an affinity for β-galactosides that have roles in neuroprotection and neuroinflammation. Several studies indicate that patients with neurodegenerative diseases have alterations in the concentration of galectins in their blood and brain. However, the results of the studies are contradictory; hence, a meta-analysis is performed to clarify whether patients with neurodegenerative diseases have elevated galectin levels compared to healthy individuals. Related publications are obtained from the databases: PubMed, Central-Conchrane, Web of Science database, OVID-EMBASE, Scope, and EBSCO host until February 2022. A pooled standard mean difference (SMD) with a 95% confidence interval (CI) is calculated by fixed-effect or random-effect model analysis. In total, 17 articles are included in the meta-analysis with a total of 905 patients. Patients with neurodegenerative diseases present a higher level of galectin expression compared to healthy individuals (MDS = 0.70, 95% CI 0.28–1.13, p = 0.001). In the subgroup analysis by galectin type, a higher galectin-3 expression is observed in patients with neurodegenerative diseases. Patients with Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALD), and Parkinson’s disease (PD) expressed higher levels of galectin-3. Patients with multiple sclerosis (MS) have higher levels of galectin-9. In conclusion, our meta-analysis shows that patients with neurovegetative diseases have higher galectin levels compared to healthy individuals. Galectin levels are associated with the type of disease, sample, detection technique, and region of origin of the patients.

show abstract

Section: Discussionmentioning

confidence: 99%